- Home
- KLTO vs QNTM Comparison
KLTO vs QNTM Comparison
Compare KLTO & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- QNTM
- Stock Information
- Founded
- KLTO 2019
- QNTM 1998
- Country
- KLTO United States
- QNTM Canada
- Employees
- KLTO N/A
- QNTM N/A
- Industry
- KLTO
- QNTM
- Sector
- KLTO
- QNTM
- Exchange
- KLTO NYSE
- QNTM NYSE
- Market Cap
- KLTO 8.3M
- QNTM 9.1M
- IPO Year
- KLTO N/A
- QNTM N/A
- Fundamental
- Price
- KLTO $0.41
- QNTM $3.42
- Analyst Decision
- KLTO
- QNTM
- Analyst Count
- KLTO 0
- QNTM 0
- Target Price
- KLTO N/A
- QNTM N/A
- AVG Volume (30 Days)
- KLTO 1.4M
- QNTM 223.5K
- Earning Date
- KLTO 02-15-2025
- QNTM 01-28-2025
- Dividend Yield
- KLTO N/A
- QNTM N/A
- EPS Growth
- KLTO N/A
- QNTM N/A
- EPS
- KLTO N/A
- QNTM N/A
- Revenue
- KLTO N/A
- QNTM N/A
- Revenue This Year
- KLTO N/A
- QNTM N/A
- Revenue Next Year
- KLTO N/A
- QNTM N/A
- P/E Ratio
- KLTO N/A
- QNTM N/A
- Revenue Growth
- KLTO N/A
- QNTM N/A
- 52 Week Low
- KLTO $0.26
- QNTM $2.70
- 52 Week High
- KLTO $13.10
- QNTM $70.85
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- QNTM 41.28
- Support Level
- KLTO N/A
- QNTM $3.20
- Resistance Level
- KLTO N/A
- QNTM $3.55
- Average True Range (ATR)
- KLTO 0.00
- QNTM 0.43
- MACD
- KLTO 0.00
- QNTM -0.00
- Stochastic Oscillator
- KLTO 0.00
- QNTM 14.97
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.